Compare SWKH & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWKH | TNYA |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Diversified Financial Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.9M | 234.8M |
| IPO Year | 1999 | 2021 |
| Metric | SWKH | TNYA |
|---|---|---|
| Price | $17.16 | $0.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.00 | $7.80 |
| AVG Volume (30 Days) | 10.3K | ★ 7.4M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $40,149,000.00 | N/A |
| Revenue This Year | $52.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.19 | ★ N/A |
| Revenue Growth | ★ 62.38 | N/A |
| 52 Week Low | $13.17 | $0.36 |
| 52 Week High | $20.49 | $2.35 |
| Indicator | SWKH | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 32.90 |
| Support Level | $17.00 | $0.66 |
| Resistance Level | $17.45 | $0.77 |
| Average True Range (ATR) | 0.28 | 0.09 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 58.94 | 11.55 |
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.